The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC

Summary

Study the effect of metformin when added to definitive locoregional radiotherapy on locoregional control and relapse rate in stage III non-small cell lung cancer patients receiving sequential chemoradiotherapy. Try to identify subsets of patients who derive maximum benefit of adding metformin to radiotherapy using innovative biomarkers.

Timeline

Start

2018-07-30

Primary completion

2021-01-08

Completion

2021-01-08

Outcome

Outcome not reported

Stopped (Business): “Loss of external funding”

Drugs

Indications